Baxter Gets Surprise Setback In Japanese Ultane Ruling
The ruling could force Baxter to stop selling the generic in Japan just eight months after the company launched the drug there. Baxter took a risk by launching the drug before the conclusion of parallel litigation in the United States.
The injunction against Baxter was likely handed down by Japan’s new patent court, which was...
To view the full article, register now.